News

The Greater Bay Area International Clinical Trial Institute (GBAICTI) held a seminar on the Hong Kong drug registration landscape on 15 April 2026, bringing together industry stakeholders for an engaging exchange of insights on regulatory developments and clinical trial advancement in Hong Kong and the Greater Bay Area (GBA).

The event highlighted Hong Kong’s growing role as a key gateway for clinical research and regulatory alignment. Expert speakers shared perspectives on navigating the evolving regulatory environment and strengthening cross‑sector collaboration to accelerate innovation.

GBAICTI extends its sincere appreciation to the Department of Health for its participation and valuable contributions to the discussion. We also thank speakers, attendees and partner organisations – including The Hong Kong Association of the Pharmaceutical Industry, the China Pharmaceutical Innovation and Research Development Association (PhIRDA), and Hong Kong Science and Technology Parks Corporation – for their contributions to the event’s success.

GBAICTI remains committed to connecting stakeholders and advancing a robust, globally competitive clinical trial ecosystem across the GBA.

For highlights of the day, please visit our LinkedIn post: https://www.linkedin.com/feed/update/urn:li:activity:7451781719751532545